A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Merck LAPs Up Tilos for Its TGFβ-Targeting Tech
2019
Cancer Discovery
Preserved Fulltext
Merck will spend up to $773 million to acquire Tilos Therapeutics, a 3-year-old startup with a series of preclinical-stage antibodies that prevent the activation and release of TGFβ, a cytokine involved in thwarting the effectiveness of cancer immunotherapies.
doi:10.1158/2159-8290.cd-nb2019-077
pmid:31253722
fatcat:xabivb63xravxjhdwfocr4tl4e